Nov 6 (Reuters) - South Korean biopharmaceutical firm
Celltrion 091990.KQ 068270.KS said its COVID-19 antibody
drug, CT-P59, was well-tolerated without significant safety
issues in the study population of its ongoing Phase 1 clinical
trial.
"Trial results indicate treatment with CT-P59 resulted in at
least 44% faster recovery time when compared with placebo," the
company said in a statement. urn:newsml:reuters.com:*:nBwVGxwla
Celltrion added that no patients treated with CT-P59 in the
study have so far required hospitalization or other antiviral
therapy as a result of COVID-19.
Last month, the South Korean drugmaker said it received
regulatory approval for Phase 3 clinical trials of the
experimental COVID-19 treatment. urn:newsml:reuters.com:*:nL4N2H311J
The company plans to seek conditional approval for CT-P59
for emergency use by the end of this year.
The treatment, the most advanced antibody drug in terms of
research in South Korea, is directed against the surface of the
coronavirus and designed to block it from locking on to human
cells.
Celltrion began commercial production of the drug in
September, which is likely to amount to around 1 million doses,
in anticipation of demand in both domestic and overseas markets.
(Reporting by Kanishka Singh in Bengaluru; Editing by Rashmi
Aich)
((Kanishka.Singh@thomsonreuters.com; +91 8061822801;))